Figure 3. Change in Migraine Disability Assessment (MIDAS) scores from baseline to month 3.

Least-squares (LS) mean changes from baseline in (A) MIDAS total, (B) absenteeism, and (C) presenteeism scores among participants with chronic migraine who were assigned to receive erenumab 70 mg, erenumab 140 mg, or placebo every month. The error bars represent 95% confidence intervals (CIs). Figure based on the efficacy analysis set. All p values ≤0.05.